Acute, subacute toxicity and genotoxic effect of Bio-Quinone® Q10 in mice and rats

被引：18

作者：

Fu, Xin ^{[1
]}

Ji, Rong ^{[2
]}

Dam, Jorgen ^{[3
]}

机构：

[1] Uppsala Univ, Dept Womens & Childrens Hlth Obstet & Gynecol, SE-75185 Uppsala, Sweden

[2] Chinese Ctr Dis Control & Prevent, Natl Inst Nutr & Food Safety, Beijing 100021, Peoples R China

[3] Pharma Trade Healthcare, SE-16308 Spanga, Sweden

来源：

REGULATORY TOXICOLOGY AND PHARMACOLOGY | 2009年 / 53卷 / 01期

关键词：

Coenzyme Q10; Toxicity; Safety; Genotoxicity; Mice; Rats; REPEATED DOSE TOXICITY; COENZYME Q(10); OXIDATIVE STRESS; CONTROLLED TRIAL; ORAL TOXICITY; DOUBLE-BLIND; DISEASE; ANTIOXIDANT; UBIQUINONE; DOSAGES;

D O I：

10.1016/j.yrtph.2008.09.003

中图分类号：

DF [法律]; D9 [法律]; R [医药、卫生];

学科分类号：

0301 ; 10 ;

摘要：

In the present study, the acute, subacute and genetic toxicity of Coenzyme Q10 (CoQ10) in the form of Bio-Quinone (R) (Pharma Nord, Denmark) was assessed. LD50 of CoQ10 by oral treatment was greater than 20 g/kg body weight in both female and male mice. Genotoxicity was assessed in mice by Ames test in Salmonella typhimurium strains TA97, TA98, TA100 and TA102, by bone marrow micronucleus test and sperm abnormality. Thirty-day subacute toxicity was conducted with oral daily dose at 0, 0.56, 1.13 and 2.25 g/kg body weight in rats. No significant changes in body weight, food intake, behavior, mortality, hematology, blood biochemistry, vital organ weight, sperm abnormality, mutagenicity and micro-nucleus formation were observed and no clinical signs or adverse effects were detected by administration of CoQ10. These results support the safety of CoQ10 for oral consumption. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：1 / 5

页数：5

共 30 条

[1]

ATAR D, 1993, CLIN INVESTIGATOR, V71, pS103

[2] Coenzyme Q10 and diabetic endotheliopathy:: oxidative stress and the 'recoupling hypothesis' [J].

Chew, GT ;

Watts, GF .

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2004, 97 (08) :537-548

[3] Assessment of coenzyme Q10 tolerability in Huntington's disease [J].

Feigin, A ;

Kieburtz, K ;

Como, P ;

Hickey, C ;

Claude, K ;

Abwender, D ;

Zimmerman, C ;

Steinberg, K ;

Shoulson, I .

MOVEMENT DISORDERS, 1996, 11 (03) :321-323

[4]

FOLKERS K, 1994, MOL ASPECTS MED, V15, P281

[5] Comparative oral toxicity of coenzyme Q10 and its (2Z)-isomer in rats:: Single and four-week repeated dose toxicity studies [J].

Hatakeyama, S ;

Kawase, S ;

Yoshimura, I .

JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 2006, 52 (01) :9-20

[6] Risk assessment for coenzyme Q10 (Ubiquinone) [J].

Hathcock, John N. ;

Shao, Andrew .

REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 45 (03) :282-288

[7] Coenzyme Q10 improves blood pressure and glycaemic control:: a controlled trial in subjects with type 2 diabetes [J].

Hodgson, JM ;

Watts, GF ;

Playford, DA ;

Burke, V ;

Croft, KD .

EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2002, 56 (11) :1137-1142

[8]

Honda Kumiko, 2007, Journal of Toxicological Sciences, V32, P437, DOI 10.2131/jts.32.437

[9] Coenzyme Q10, a cutaneous antioxidant and energizer [J].

Hoppe, U ;

Bergemann, J ;

Diembeck, W ;

Ennen, J ;

Gohla, S ;

Harris, I ;

Jacob, J ;

Kielholz, J ;

Mei, W ;

Pollet, D ;

Schachtschabel, D ;

Sauermann, G ;

Schreiner, V ;

Stäb, F ;

Steckel, F .

BIOFACTORS, 1999, 9 (2-4) :371-378

[10] Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial [J].

Ikematsu, H ;

Nakamura, K ;

Harashima, S ;

Fujii, K ;

Fukutomi, N .

REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) :212-218

← 1 2 3 →